The rapid advance of pharmacogenomics and targeted medicine has aroused scientific interest in biomarkers, combined with the fact that nearly all prostate cancer patients will develop inevitable resistance to AR‐targeted therapies; therefore, identifying patients with shorter response time is particularly germane for timely treatment replacement. This evidence concerns the gene AR and prostate carcinoma.